Attorney Docket No.: **DEX-0522**

Inventors:

Salceda et al.

Serial No.:

Not yet assigned

Filing Date:

Herewith

Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (original): An isolated nucleic acid molecule comprising

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 95-156;
- (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-94;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
- (d) has at least 95% sequence identity to the nucleic acid molecule of (a) or (b).

Claim 2 (original): The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.

Claim 3 (original): The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.

Claim 4 (original): The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is an RNA.

Claim 5 (original): The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a mammalian nucleic acid molecule.

Attorney Docket No.: DEX-0522

Inventors: Serial No.: Salceda et al. Not yet assigned

Filing Date:

Herewith

Page 3

Claim 6 (original): The nucleic acid molecule according to claim 5, wherein the nucleic acid molecule is a human nucleic acid molecule.

Claim 7 (currently amended): A method for determining the presence of a breast specific nucleic acid (BSNA) in a sample, comprising the steps of:

- (a) contacting the sample with the nucleic acid molecule of SEQ ID NO:1-94 according to claim 1 under conditions in which the nucleic acid molecule will selectively hybridize to a breast specific nucleic acid; and
- detecting hybridization of the nucleic acid molecule to a BSNA in the sample, wherein the detection of the hybridization indicates the presence of a BSNA in the sample.

Claim 8 (original): A vector comprising the nucleic acid molecule of claim 1.

Claim 9 (original): A host cell comprising the vector according to claim 7.

Claim 10 (original): A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of:

- (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and
 - (b) incubating the host cell under conditions in which the

DEX-0522

Inventors:

Salceda et al.
Not yet assigned

Serial No.: Filing Date:

Herewith

Page 4

polypeptide is produced.

Claim 11: (original) A polypeptide encoded by the nucleic acid molecule according to claim 1.

Claim 12 (currently amended): An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 95-156; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:1-94.

Claim 13 (currently amended): An antibody or fragment thereof that specifically binds to: the polypeptide according to claim 11, (a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 95-156; or (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:1-94.

Claim 14 (currently amended): A method for determining the presence of a breast specific protein in a sample, comprising the steps of:

(a) contacting the sample with a suitable reagent in which the reagent will which selectively interact interacts with the breast-specific protein comprising an amino acid sequence with at least 95% identity to SEQ ID NO:95-156 the polypeptide according

DEX-0522

Inventors:
Serial No.:

Salceda et al. Not yet assigned

Filing Date:

Herewith

Page 5

to claim 11, a polypeptide comprising an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 95-156 or a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:1-94; and

(b) detecting the interaction of the reagent with a breast specific any protein in the sample, wherein the detection of binding interaction of the reagent indicates the presence of a breast specific protein in the sample.

Claim 15 (currently amended): A method for diagnosing and monitoring the presence and metastases of breast cancer in a patient, comprising the steps of:

- (a) determining an amount of:
- (i) a nucleic acid molecule comprising a nucleic-acid sequence that encodes an amino acid sequence of SEQ-ID-NO:95-156;
- (ii) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:1-94;
- (iii) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (i) or (ii);
- (iv) a nucleic acid molecule having at least 95% identity to the nucleic acid molecule of (i) or (ii);

an isolated nucleic acid molecule of claim 1, (v) a polypeptide comprising an amino acid sequence with at least 95% identity to $\frac{1}{2}$ SEQ ID NO:95-156; or

(vi) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of

DEX-0522

Inventors:
Serial No.:

Salceda et al.
Not yet assigned

Filing Date:

Herewith

Page 6

SEQ ID NO:1-94 and; and

(b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the breast specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of breast cancer.

Claim 16 (currently amended): A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO:95-156;
- (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-94;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b);
- (d) a nucleic acid molecule having at least-95%-sequence identity to the nucleic acid molecule of (a) or (b);
- an isolated nucleic acid molecule of claim 1; (e) a polypeptide comprising an amino acid sequence with at least 95% identity to of SEQ ID NO:95-156; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:1-94.

Claim 17 (currently amended): A method of treating a patient

DEX-0522

Inventors:

Salceda et al.
Not yet assigned

Serial No.: Filing Date:

Herewith

Page 7

with breast cancer, comprising the step of administering a composition consisting of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO:95-156;
- (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-94;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b);
- (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b) an isolated nucleic acid molecule of claim 1;
- (e) a polypeptide comprising an amino acid sequence with at least 95% identity to ef SEQ ID NO:95-156; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEO ID NO:1-94.

Claim 18 (original): A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 12.